China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China
SHENZHEN, CHINA – On June 25, China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or...